Macrophage ADAM17 Deficiency Augments CD36-Dependent Apoptotic Cell Uptake and the Linked Anti-Inflammatory Phenotype

Will S. Driscoll1, Tomas Vaisar2, Jingjing Tang1, Carole L. Wilson1, Elaine W. Raines1

Departments of 1Pathology, and; 2Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington School of Medicine, Seattle, WA

Running title: ADAM17 Limits CD36-Mediated Apoptotic Cell Uptake

Subject codes:
[97] Other vascular biology
[131] Apoptosis
[137] Cell biology/structural biology
[138] Cell signaling/signal transduction
[144] Genetically altered mice

Address correspondence to:
Dr. Elaine W. Raines
University of Washington School of Medicine
Department of Pathology
Harborview Medical Center, Box 359675
325 - 9th Avenue
Seattle, WA 98104
Tel: (206) 897-5410
Fax: (206) 897-5416
ewraines@u.washington.edu

In March 2013, the average time from submission to first decision for all original research papers submitted to Circulation Research was 14.5 days.
ABSTRACT

Rationale: Apoptotic cell phagocytosis (efferocytosis) is mediated by specific receptors and is essential for resolution of inflammation. In chronic inflammation, apoptotic cell clearance is dysfunctional and soluble levels of several apoptotic cell receptors are elevated. Reports have identified proteolytic cleavage as a mechanism capable of releasing soluble apoptotic cell receptors, but the functional implications of their proteolysis are unclear.

Objective: To test the hypothesis that ADAM17-mediated cleavage of apoptotic cell receptors limits efferocytosis in vivo.

Methods and Results: In vivo comparison of macrophage efferocytosis in wildtype and Adam17-null hematopoietic chimeras demonstrates that ADAM17 deficiency leads to a 60% increase in efferocytosis and an enhanced anti-inflammatory phenotype in a model of peritonitis. In vitro uptake of phosphatidylserine liposomes identifies the dual-pass apoptotic cell receptor CD36 as a major contributor to enhanced efferocytosis, and CD36 surface levels are elevated on macrophages from Adam17-null mice. Further, temporal elevation of CD36 expression with inflammation may also contribute to its impact. Soluble CD36 from macrophage-conditioned media is comprised of two species based on Western blotting, and mass spectrometry identifies three N-terminal peptides, which represent probable cleavage sites. Levels of soluble CD36 are decreased in Adam17-null conditioned media, providing evidence for involvement of ADAM17 in CD36 cleavage. Importantly, enhanced efferocytosis in vivo by macrophages lacking ADAM17 is CD36 dependent and accelerates macrophage clearance from the peritoneum, thus promoting resolution of inflammation and highlighting the impact of increased apoptotic cell uptake.

Conclusions: Our studies demonstrate the importance of ADAM17-mediated proteolysis for in vivo efferocytosis regulation, and suggest a possible mechanistic link between chronic inflammation and defective efferocytosis.

Keywords: Proteolysis, metalloproteinase, inflammation, macrophage, apoptotic cells

Nonstandard Abbreviations:
acLDL acetyl low-density lipoprotein
iNOS inducible nitric oxide synthase
LCMS liquid chromatography-mass spectrometry
LOX-1 lectin-type oxidized low-density lipoprotein receptor
MerTK Mer tyrosine kinase
MS mass spectrometry
PS phosphatidylserine
SR scavenger receptor
SR-PSOX scavenger receptor for phosphatidylserine and oxidized LDL
TNF tumor necrosis factor
WT wildtype
INTRODUCTION

Efficient phagocytosis of apoptotic cells (efferocytosis) is an essential component of tissue homeostasis, wound healing, and the resolution of inflammation. Professional phagocytes, such as macrophages, employ a variety of transmembrane receptors to rapidly recognize and ingest apoptotic cells. After engulfing an apoptotic cell, macrophages actively dampen inflammation by releasing anti-inflammatory cytokines such as transforming growth factor-β and interleukin-10, as well as pro-resolving lipid mediators and eicosanoids which promote macrophage efflux and the resolution of inflammation. However, if apoptotic cells are not rapidly cleared, secondary necrosis ensues, resulting in leakage of toxic intracellular antigens, tissue damage, and amplified inflammation. Defective efferocytosis is frequently observed in the context of chronic inflammation, with pathological sequelae ranging from non-resolving foot ulcers in diabetes to necrotic core expansion in atherosclerosis. However, the underlying mechanisms responsible for deficient apoptotic cell uptake are poorly understood.

Biological fluids from patients with chronic inflammatory diseases also show elevated levels of soluble apoptotic cell receptors, including CD36, Mer tyrosine kinase (MerTK), and lectin-type oxidized LDL receptor (LOX)-1. CD36 is a two-pass transmembrane receptor, while MerTK and LOX-1 are type I and type II transmembrane proteins, respectively. MerTK and LOX-1 can be proteolytically cleaved by the transmembrane protease ADAM17. Although the ubiquitously expressed ADAM17 was first described for its role in the shedding of cell-associated tumor necrosis factor-α, it has since been shown to cleave a variety of cell surface proteins involved in inflammation. Regulation of ADAM17 is poorly understood, and lack of reagents to monitor its levels and activity have hampered progress. Unlike soluble enzymes that cleave substrates at specific consensus sequences, ADAM17 cleaves its substrates at a membrane-proximal site in which stalk length and distance from the membrane appear to be important. ADAM17 membrane proximal cleavage of its substrates releases almost the entire extracellular domain, and the soluble ectodomain can often act as an antagonist, which has been shown for LOX-1 and MerTK. Thus proteolysis of apoptotic cell receptors has the potential to rapidly decrease receptor surface levels and release a soluble antagonist, both of which could exacerbate deficient efferocytosis. However, the functional contribution of proteolysis to the regulation of apoptotic cell uptake in vivo has not been tested.

The current investigation tests the hypothesis that efferocytosis and its concomitant anti-inflammatory consequences are limited by proteolytic cleavage of apoptotic cell receptors from the macrophage surface. We show that ADAM17 deletion enhances macrophage-mediated efferocytosis in vivo, resulting in an augmented anti-inflammatory response. Additionally, we report that macrophage CD36 surface levels are elevated in the absence of ADAM17, and that there are three probable N-terminal cleavage sites in CD36. The absence of ADAM17 leads to a decrease in soluble CD36 levels. Blockade of CD36 in vivo is sufficient to abolish enhanced efferocytosis by Adam17-null macrophages, a process which also accelerates resolution of inflammation. Together these studies establish that ADAM17-mediated proteolysis of CD36 is an important post-translational mechanism controlling apoptotic cell phagocytosis, inflammation and its resolution.

METHODS

An expanded Methods section describing all procedures is available in the Online Data Supplement at http://circres.ahajournals.org

DOI: 10.1161/CIRCRESAHA.113.300683
**Hematopoietic chimeric mice.**

*Adam17ΔEx5/ΔEx5* (*Adam17* -/-) or WT hematopoietic chimeras were generated as previously described using C57BL/6 ES cells.21, 22 All mouse experiments were approved by the University of Washington Institutional Animal Care and Use Committee.

**Sterile peritonitis model.**

Thioglycollate peritonitis was induced by injection of 1 ml of 4% sterile thioglycollate (BD Diagnostic, 2321398). Peritoneal cells (thioglycollate-elicited cells) were collected after 4 days by injection and removal of 5 ml PBS containing 5 mmol/L EDTA.

**Flow cytometry.**

Staining of freshly isolated cells for flow cytometric analyses (FACScan, BD Pharmingen, 10-50,000 events) used antibodies listed in the Online Data Supplement. Flow data were analyzed using FlowJo 7.5 software (TreeStar).

**Fab preparation.**

Protein-L purified IgAs from hybridoma media (anti-CD36, Clone CRF-D 2717, Roy Silverstein), or non-immune IgA (Sigma Aldrich, M-1421), were partially reduced to facilitate papain cleavage,23 and incubated with immobilized papain (Pierce, 20341) to generate Fab fragments.

**In vivo efferocytosis.**

Thymuses (4-6 week C57BL/6 mice) were harvested, mechanically dissociated and filtered to yield a single-cell suspension. Thymocytes were labeled with TAMRA-SE dye (Molecular Probes, C-1171), and in vivo analysis of apoptotic cell uptake was performed.24

**Liposome binding and uptake.**

Phosphatidylserine (PS)-rich liposomes (equal parts PS to phosphatidylcholine) were prepared with a 1% mole fraction of the fluorescent dye, 1-dioctadecyl-3,3-tetramethylindocarbocyanin perchlorate (DiI, Sigma, 42364) by extrusion through a 0.1 μm polycarbonate membrane.25 Thioglycollate-elicited cells from WT or ADAM17 null hematopoietic chimeras were plated and macrophages (> 95%) adherent after 2 hours were used for binding and uptake studies.

**Soluble CD36 characterization.**

Thioglycollate-elicited macrophages were plated 2 hours and adherent cells were cultured with 1,000,000 U/L human macrophage colony-stimulating factor (gift from Chiron), or other stimulants, in Opti-MEM (Invitrogen) for 4, 6 or 24 hours at 37°C. Conditioned media was centrifuged at 300 x g for 10 minutes to remove cell debris, followed by 28,300 x g for 140 minutes at 4°C to minimize microparticle content,26 and levels of CD36 were determined by ELISA using antibodies recognizing the extracellular domain of CD36. The resulting media were directly run on SDS-PAGE for Western analysis, or immunoprecipitated and run on SDS-PAGE for mass spectrometry (MS).

**Identification of potential cleavage sites in soluble CD36.**

Gel bands corresponding to CD36 were detected by Coomassie staining, and were verified by CD36 immunoblot analysis of adjacent lanes. CD36 fractions were excised, subjected to standard in-gel digestion with trypsin, and digested peptides were analyzed by liquid chromatography-mass spectrometry (LCMS) analysis.

**Statistical analysis.**

For statistical analysis, the Student’s *t*-test was performed using the InStat software, version 3.0b. All error bars represent standard error of the mean.
RESULTS

In vivo efferocytosis is enhanced in macrophages lacking ADAM17.

To test the hypothesis that efferocytosis and its downstream anti-inflammatory response are limited by proteolytic cleavage of macrophage apoptotic cell receptors, we evaluated the effect of leukocyte-specific deletion of the transmembrane protease ADAM17 on apoptotic cell phagocytosis in vivo. Adam17-null and WT hematopoietic chimeras were injected intraperitoneally with the sterile irritant thioglycollate to promote inflammatory monocyte influx. At 96 hours after thioglycollate, levels of cytokines released early in the response (2-4 hours) have abated and the influx of neutrophils has cleared (48 hours) leaving F4/80+ macrophages as the major leukocyte (>85%) in the peritoneal cavity.21 Fluorescently-labeled control or apoptotic thymocytes were injected into the peritoneum to evaluate efferocytosis (Figure 1A). No difference in thymocyte uptake between Adam17-null and WT macrophages is observed following injection of either healthy control or opsonized thymocytes (Figure 1B). In contrast, administration of apoptotic thymocytes demonstrates a 1.6-fold increase in Adam17-null macrophage binding and uptake of apoptotic cells relative to WT (Figure 1B). Uptake of fluorescently labeled apoptotic thymocytes was confirmed by fluorescent microscopy (Supplemental Figure 1). This significant increase in macrophage-mediated efferocytosis suggests that ADAM17 may directly or indirectly change levels of one or more apoptotic cell receptors.

Mixed hematopoietic chimeras containing a 50% mixture of Adam17-null and WT bone marrow were evaluated to determine whether efferocytosis in the absence of ADAM17 is indirectly increased as a result of alteration of the extracellular inflammatory environment, for example by soluble mediators. Although both Adam17-null and WT cells in the mixed chimeras are exposed to an identical extracellular milieu, Adam17-null macrophages still display enhanced efferocytosis (Figure 1B). These results indicate that the increase in apoptotic cell phagocytosis by Adam17-null macrophages is cell intrinsic and directly impacts apoptotic cell receptor function.

Efferocytosis has been shown to actively inhibit the macrophage inflammatory response.2 To evaluate whether elevated apoptotic cell uptake alters the inflammatory phenotype of Adam17-null macrophages, intracellular protein levels of arginase I and inducible nitric oxide synthase (iNOS) were compared by flow cytometry following injection of apoptotic thymocytes (representative histograms in Supplemental Figure 2), healthy thymocytes or PBS. Following in vivo uptake of apoptotic cells, Adam17-null macrophages show a 34% elevation in arginase I levels relative to WT (Figure 1C). In addition, subsequent inflammatory stimulation ex vivo leads to a 45% reduction in iNOS induction in the null macrophages (Figure 1D). No differences in arginase I or iNOS levels were observed in Adam17-null or WT macrophages injected with control thymocytes (Figure 1C and D). Although we can’t eliminate the possibility that prior uptake of apoptotic neutrophils during the thioglycollate response may alter macrophage phenotype and/or efferocytosis, Adam17-null macrophages did not demonstrate altered arginase signaling detectable at 96 hours. Overall, ADAM17 deletion significantly augments the macrophage efferocytosis-induced anti-inflammatory phenotype.

Increased phosphatidylserine liposome binding/uptake by Adam17-null macrophages is CD36 dependent and is associated with elevated CD36 surface levels.

Macrophages express a variety of apoptotic cell receptors that may be modulated by ADAM17. Since macrophage efferocytosis is dependent upon apoptotic cell receptor recognition of phosphatidylserine (PS) exposed by cells undergoing apoptosis,2 PS liposomes were employed as a surrogate for apoptotic cells for an in vitro screen of potential receptors responsible for the enhanced efferocytosis by Adam17-null macrophages. Adam17-null peritoneal macrophages bind more PS liposomes in vitro (Figure 2A and 2C), but not phosphatidylcholine liposomes (data not shown), suggesting that ADAM17 deletion results
in elevated levels of receptors that recognize PS exposed on apoptotic cells. Similar results were obtained with Adam17-null versus WT bone-marrow-derived macrophages (Figure 2B). Although many apoptotic cell receptors can bind PS, a unique subset of receptors shares an affinity for acetylated LDL (acLDL) as a ligand. When acLDL is added with PS liposomes, the ADAM17-dependent difference in PS liposome binding is abolished (Figure 2A). This finding suggests that the receptors responsible for elevated liposome binding by Adam17-null macrophages have the ability to directly bind both acLDL and PS liposomes – a trait shared by CD36 and SR-B1.27 However, SR-B1 surface levels were not detectable above isotype control staining of WT or Adam17 null macrophages (data not shown), thus focusing our attention on CD36.

To first directly test the role of CD36 in the enhanced in vitro liposome binding and uptake by Adam17-null macrophages, the extent of inhibition by anti-CD36 or isotype control antibody was evaluated (Figure 2C). CD36 blockade abolishes the differential liposome uptake by Adam17-null peritoneal macrophages, and significantly reduces uptake by both Adam17-null and WT macrophages. In contrast, blocking antibody to SR-A, a prominent scavenger receptor, has no significant effect. Together these data identify CD36 as the primary apoptotic cell receptor leading to enhanced PS liposome binding and uptake in vitro by Adam17-null macrophages.

To more broadly screen for possible changes in apoptotic cell receptor surface levels, freshly isolated thioglycollate-elicited peritoneal macrophages from WT and Adam17-null chimeras were analyzed by flow cytometry. ADAM17 deletion results in a 30% increase in macrophage surface CD36 but no difference in other apoptotic cell receptors (Figure 3A), although MerTK, LOX-1 and SR-PSOX are reported substrates of ADAM17.12, 13, 28 CD36 surface levels are elevated to a similar extent on Adam17-null macrophages from mixed hematopoietic chimeras (data not shown), indicating a cell autonomous trait. Interestingly, CD36 surface levels are low in resident peritoneal macrophages but increase after thioglycollate injection, reaching a maximum at 96 hours (Figure 3B-D). These results suggest that CD36 may be important during the resolution phase of inflammation.2, 29 Also, no difference in CD36 mRNA levels is observed by qPCR analysis of Adam17-null and WT macrophages (data not shown), suggesting that ADAM17-dependent mechanisms regulate CD36 surface levels post-translationally. The combined data showing an acLDL-sensitive increase in PS liposome binding and uptake by Adam17-null macrophages, as well as elevated CD36 surface levels, implicate CD36 as a major target of ADAM17.

**ADAM17 deletion reduces levels of soluble CD36.**

Elevated macrophage CD36 surface levels would be expected to coincide with decreased release of soluble CD36. To evaluate whether levels of soluble CD36 are altered by ADAM17 deficiency, 24-hour conditioned media were collected from adherent Adam17-null and WT peritoneal macrophages. To reduce potential microvesicle content, the media were centrifuged at high speed, which depletes microvesicles by ~75%.26 Quantification of media CD36 levels by ELISA using antibodies to the CD36 extracellular domain shows that ADAM17 deletion reduces the ratio of soluble/cellular CD36 by 25.8% (Figure 4A). Soluble forms of CD36 are not due to alternative splicing since this has been shown to occur in the 5’ noncoding region in all identified variants.30 Release of soluble CD36 from WT peritoneal macrophages was also investigated following 4-hour stimulation with PBS, LPS and interleukin (IL)-4 (Figure 4B). Although shedding of tumor necrosis factor (TNF) receptor II, another substrate of ADAM17, was increased more than 5-fold following LPS stimulation (Figure 4B), neither LPS nor IL-4 increased levels of soluble CD36 relative to PBS, suggesting its release is primarily constitutive.

Since CD36 is a highly glycosylated protein, Western analysis was performed following PNGase F treatment of media samples to assess molecular species (Figure 4C and 4D). Conditioned media (24-hour) from WT macrophages show primarily two regions of staining with apparent molecular weights of ~52 and ~47 kDa (Figure 4C). The ~47 kDa region appears as a doublet, although detection of two distinct
species is variable. However, CD36 levels in both the ∼52 and ∼47 kDa regions are reduced in conditioned media from Adam17-null macrophages relative to WT. The ∼47 kDa region is also detected in 6-hour conditioned media (Figure 4D), consistent with it not being a degradation product of the longer 24-hour incubation. Together, these observations provide the first evidence for a role of ADAM17 in the proteolytic release of soluble CD36.

**Mass spectrometry identifies three probable N-terminal cleavage sites in soluble CD36.**

CD36 is predicted to be a dual-pass transmembrane protein with considerable extracellular topology (Figure 5A). To further characterize the species in soluble CD36 detected by Western analysis, conditioned media from WT macrophages were immunoprecipitated with anti-CD36 and three fractions were cut (Figure 5B) from the Coomassie-stained gel to include the ∼52kDa region (fraction A), the zone between the two regions (fraction B) and the ∼47kDa region (fraction C). In-gel tryptic digest followed by mass spectrometry was performed on each of the excised gel fractions. Mass spectrometry unequivocally identified CD36 in all fractions with high sequence coverage (A, 31%; B, 34%; and C, 32%), and all peptides included segments of the extracellular domain (Figure 5C). The prediction would be that peptides from both the N- and C-terminal regions of the extracellular domain with non-tryptic cleavage sites should be detected for soluble CD36.

Mass spectrometric analysis identified three N-terminal semi-tryptic peptides (Figure 5A, 5C and Supplemental Figure 3). Peptide N1 results from a non-tryptic proteolytic cleavage between Gly23-Gly24. This unique cleavage site is estimated to be six amino-acids within the extracellular side of the putative N-terminal transmembrane domain (http://uniprot.org), which is not a typical cleavage site for ADAM17. Cleavage 12 amino acids from the transmembrane domain between Glu41-Val42, a more typical pattern for ADAM17, gives rise to peptide N2. Peptide N3 consists of amino acids 139-163 and contains the ADAM17 preferred amino acids alanine at the P1 position and valine at the P1’ position of the cleavage site as observed for several ADAM17 substrates including tumor necrosis factor-. Although the N3 peptide is a greater distance from the transmembrane domain than other reported ADAM17 cleavage sites, it is adjacent to a hydrophobic region between amino acids 184 and 204 (Figure 5A and 5C) that may interact with the plasma membrane.

Only one semi-tryptic peptide (C1) was identified in the C-terminal portion of CD36 (Figure 5A, 5C and Supplemental Figure 3D). Because its cleavage site is 95 amino acids from the C-terminal transmembrane domain, ADAM17 cleavage at this site is unlikely. However, because ADAM17 may share cleavage sites with trypsin (http://merops.sanger.ac.uk), it is possible that some tryptic peptides actually result from ADAM17 cleavage such as trypic peptides with a C-terminal cleavage site at K426 and/or K430 (Figure 4C). Use of alternative enzymes for proteomics analysis would help address this issue. Nevertheless, our data provide strong evidence for proteolytic cleavage of CD36.

**Increased in vivo apoptotic cell phagocytosis by Adam17-null macrophages is CD36 dependent and promotes accelerated resolution of inflammation.**

We next sought to directly test the contribution of CD36 to enhanced efferocytosis by Adam17-null macrophages in vivo. CD36-blocking or isotype control Fab were injected at the same time as the fluorescently-labeled apoptotic thymocytes into the peritoneum of chimeras. Fab was used to avoid CD36 dimerization and activation that occurs with whole IgA. CD36 blockade significantly decreases efferocytosis by Adam17-null, but not WT, macrophages (Figure 6A). The absence of an effect on apoptotic cell uptake by WT macrophages in vivo as compared with in vitro liposome uptake (Figure 2C) may be due to a disparate response to whole IgA used in the in vitro screen or differences in the effective dosage required in vivo. However, these in vivo data establish that CD36-mediated apoptotic cell phagocytosis is selectively enhanced in the absence of ADAM17.
To investigate in vivo relevance of enhanced efferocytosis by Adam17-null macrophages, we asked whether resolution of the inflammatory response was enhanced following injection of apoptotic thymocytes. Administration of apoptotic thymocytes led to a 33% reduction in the number of WT macrophages within 30 minutes (Figure 6B), indicating that apoptotic cell uptake enhances macrophage clearance and inflammation resolution. Injection of healthy thymocytes or PBS had no effect on macrophage numbers, suggesting no cell-intrinsic acceleration of macrophage exiting at 96 hours. In contrast to WT macrophages, Adam17-null macrophage numbers were reduced 56% in response to efferocytosis (Figure 6B), demonstrating accelerated exiting and highlighting the in vivo impact of increased apoptotic cell uptake in the absence of ADAM17.

**DISCUSSION**

This study demonstrates for the first time that in vivo efferocytosis and its associated anti-inflammatory effects are enhanced by ADAM17 deletion, suggesting that ADAM17 normally functions to limit apoptotic cell phagocytosis. Unexpectedly, the major target of ADAM17 appears to be the dual-pass scavenger receptor CD36; its surface levels are elevated in the absence of ADAM17 and the ratio of soluble to cell-associated CD36 is decreased by 25.8%. Further, in the sterile peritonitis model, we detect no Adam17-dependent alterations in surface levels of any other major apoptotic cell receptors, including LOX-1 and MerTK, which were previously implicated as substrates of ADAM17. Using mass spectrometry, three novel N-terminal peptides and one C-terminal peptide were detected in soluble CD36 that represent probable cleavage sites. In addition, we establish that enhanced in vivo efferocytosis in the absence of ADAM17 is CD36 dependent, and leads to accelerated clearance of macrophages. These data provide evidence for ADAM17 involvement in the shedding of a dual-pass transmembrane protein, and demonstrate the importance of proteolysis in controlling apoptotic cell uptake and resolution of inflammation associated with apoptotic cell uptake.

Recent reports have shown that ADAM17 can cleave MerTK and LOX-1 in vitro, and thus they were particularly likely targets. However, we demonstrate no change in surface levels of either of these receptors in vivo, while CD36 levels are elevated in the absence of ADAM17. A likely explanation for the lack of effect on either MerTK or LOX-1 is that in vitro analyses have shown that their shedding requires stimulation with LPS or tumor necrosis factor-α, respectively. Thus, ADAM17 cleavage of MerTK and LOX-1 may play a more significant role in responses to pathogens and/or on classically activated macrophages.

The ADAM17-dependent correlation between macrophage CD36 surface levels and in vivo enhanced efferocytosis further highlights the importance of CD36 as an apoptotic cell receptor. Previous experiments in CD36-deficient mice established that apoptotic cell burden in wound tissue is 2 to 3-fold greater than in WT mice, and in vitro efferocytosis was reduced by ~40% in CD36-deficient macrophages. In our studies, elevated surface levels of CD36 in the absence of ADAM17 led to increased apoptotic cell uptake by inflammatory macrophages in vivo, and we demonstrate that the majority of ADAM17-dependent enhanced efferocytosis is abolished by CD36 blockade. Low levels of expression of CD36 on resident tissue and peritoneal macrophages and highest CD36 expression on inflammatory macrophages during the resolution phase suggest that its role in efferocytosis may be more important for inflammatory responses than for normal homeostasis. Further, we show that acceleration of macrophage clearance from the peritoneum is dependent upon apoptotic cell uptake. Together these data suggest a temporal and context-dependency for ADAM17 modulation of the resolution of inflammation.

To biochemically characterize soluble CD36, we analyzed media collected from cultured WT peritoneal macrophages, and our MS analysis uncovered three probable N-terminal cleavage sites.

DOI: 10.1161/CIRCRESAHA.113.300683
ADAM17 normally cleaves the extracellular stalk of its substrates proximal to the transmembrane domain (typically within 15 amino acids) with some preferences for particular residues flanking the cleavage site. The non-tryptic N-terminus of peptide N1 is estimated to be six amino acids into the putative transmembrane domain, and therefore is less likely to be a direct target of ADAM17. Since we cannot distinguish between ADAM17 involvement in primary and secondary cleavage events, it is possible that initial ADAM17-dependent cleavage of CD36 at N2, N3 or another site leads to activation of regulated intramembrane proteolysis, such as that mediated by γ-secretases, or that ADAM17 modulates cleavage by another protease and does not directly target CD36. With a cleavage site 12 amino acids from the transmembrane domain, peptide N2 is more typical of ADAM17 cleavage. In contrast, peptide N3 is 113 amino acids from the transmembrane domain, but 45 amino acids from a hydrophobic region of CD36 that may interact with the plasma membrane, and thus may localize the N3 cleavage site in a juxtamembrane position that favors interaction with ADAM17 (Figure 5A). It also contains alanine and valine preferred by ADAM17 in the P1 and P1’ position, respectively. Functionally, both N2 and N3 cleavage would likely disrupt the domain of CD36 (amino acids 155-183) implicated in macrophage phagocytosis of apoptotic cells. We identified only one C-terminal non-tryptic peptide (C1), and since it is 95 amino acids from the C-terminal transmembrane domain, it likely results from cleavage by an enzyme other than ADAM17. Since ADAM17 deletion only inhibits release of soluble CD36 by 25%, other proteases may be involved in liberation of soluble CD36, such as ADAM10 or multiple other ADAM proteases expressed by peritoneal and bone marrow-derived macrophages (Supplemental Figure 4). Detailed structural data for CD36 and a better understanding of its processing would facilitate interpretation of our data. Although we do not yet understand how soluble CD36 is released from the cell, our data collectively implicate ADAM17 in the shedding of CD36, and establish a role for ADAM17 in the regulation of surface levels of the ditopic transmembrane receptor CD36.

CD36 levels in serum are increased in several chronic inflammatory diseases, and have been found to positively correlate with mortality, type 2 diabetes, and atherosclerotic disease severity. However, the biochemical nature of soluble CD36 has not been evaluated in these contexts. A recent study suggested that the soluble CD36 found in the plasma of healthy donors is full-length CD36 and is a component of microparticles. Although this study analyzed isolated fractions by Western blot analysis and failed to detect CD36 in the microparticle-depleted platelet-free plasma, technical issues with the analysis of plasma may have limited the sensitivity of detection. Given the already robust correlations of soluble levels of CD36 with disease severity and early detection, we plan to investigate the relative distribution of soluble CD36 in microparticles and cleaved soluble forms in different disease states, which could significantly enhance their usefulness as biomarkers. Our analysis of WT macrophage conditioned media in vitro showed a relative distribution of 0.48 +/- 0.038% in media depleted of microparticles and 0.042 +/- 0.001% in the microparticle pellet following ultracentrifugation, both relative to cell lysate CD36 (n=3/group). In the absence of ADAM17, CD36 in media was decreased 25.8% (p =0.011, n=3) and microparticle pellet content was increased by 14.3% (p =0.023, n=3). Our data suggest that under these in vitro conditions, shed CD36 in media is a more significant contributor than microparticle-derived CD36. More detailed biochemical analysis is needed to determine the extent to which soluble CD36 in chronic inflammatory diseases may result from ADAM17-mediated shedding.

Our studies have focused on enhanced uptake of apoptotic cells in the absence of macrophage ADAM17 and identified CD36 as the primary apoptotic cell receptor targeted by ADAM17. The increased ADAM17-mediated CD36 shedding uncovered in our study may provide a mechanistic link between the non-resolving nature of certain diseases and defective apoptotic cell phagocytosis. However, in addition to apoptotic cell uptake, CD36 has a number of other functions, such as uptake of pathogens and modified low-density lipoproteins important in inflammatory responses including atherosclerosis, mediation of long-chain fatty acid uptake and transport into cells involved in metabolic disorders, and binding thrombospondin and related proteins to inhibit angiogenesis in wound healing and various pathologies. Essential to these other functions is CD36 assembly of signaling complexes, most likely...
mediated by the C-terminal cytoplasmic domain. Proteolysis would disable this downstream pathway, and thus it is likely that this mechanism has even broader implications for inflammation and disease pathogenesis than has been uncovered in our investigations. Therefore, it will be important for future studies to define the role of proteolysis in the multiple additional functions of CD36 in normal homeostasis and pathology.

ACKNOWLEDGMENTS
We thank Roy L. Silverstein (Medical College of Wisconsin) and Debra Rateri (University of Kentucky) for providing of antibodies to CD36 (Clone CRF-D 2717) and SR-A (guinea pig polyclonal), respectively. We also thank Cindy Chang for excellent technical assistance.

SOURCES OF FUNDING
This work was partially supported by grants from the NIH P01 HL018645 to EWR, TV by P01 HL092969, and WSD by an American Heart Association Predoctoral Fellowship and NIH Training Grant T32 HL07312. Mass spectrometric analysis was funded by NIH P30 DK017047 to the Diabetes Research Center and the University of Washington’s Proteomics Resource (UWPR95794).

DISCLOSURES
None

REFERENCES


FIGURE LEGENDS

Figure 1: Increased in vivo efferocytosis of apoptotic thymocytes by Adam17-null macrophages is cell autonomous, and shifts them to a less inflammatory phenotype. A. The scheme for in vivo peritoneal macrophage uptake of TAMRA-labeled apoptotic thymocytes is shown. Healthy thymocytes and opsonized thymocytes were evaluated as controls. B. WT, Adam17-null, or mixed hematopoietic chimera mice that have ~50% WT and ~50% Adam17-null leukocytes were injected with the indicated thymocytes. The percent of TAMRA-positive macrophages was assessed by flow cytometry. C. Following in vivo exposure to PBS, healthy or apoptotic thymocytes, Adam17-null or WT macrophages were analyzed immediately following harvest for intracellular levels of arginase I, or D. cultured ex-vivo for 20 hours with lipopolysaccharide and IFNγ and analyzed for intracellular iNOS by flow cytometry. Numbers in the bars indicate the number of mice evaluated, and p values for significant differences are shown.

Figure 2: Adam17-null peritoneal and bone marrow-derived macrophages show increased phosphatidylserine liposome binding/uptake, and peritoneal macrophage uptake is CD36-dependent. A. Peritoneal macrophages from WT or Adam17-null hematopoietic chimera mice were harvested 96 hours after thioglycollate injection, and either plated and treated with or without acetylated-LDL at 4°C for 15 minutes followed by incubation with 40 µmol/L fluorescently labeled phosphatidylserine (PS) liposomes for 4 hours at 4°C. B. Bone-marrow-derived macrophages were isolated from whole bone marrow of WT or Adam17-null hematopoietic chimera mice and cultured for 7 days with M-CSF. Adherent cells were replated, and PS liposome binding was monitored as described in A. C. Peritoneal macrophages were plated and incubated with 160 µmol/L fluorescently labeled PS liposomes and 5 mg/L of either receptor-blocking or isotype control antibody for one hour at 37°C. Fluorescence was assessed by flow cytometry, numbers within the bars indicate the number of mice evaluated, and p values for significant differences are shown.

Figure 3: Cell surface levels of CD36 are elevated on peritoneal macrophages lacking ADAM17, and maximal expression of CD36 on WT macrophages is during the resolution phase of peritonitis. WT resident peritoneal macrophages (Res) or peritoneal macrophages from WT or Adam17-null hematopoietic chimera mice were harvested at different times after thioglycollate injection and immediately stained with antibodies to the indicated apoptotic cell receptors and evaluated by flow cytometry. A. Levels of different apoptotic cell receptors were evaluated 96 hours after thioglycollate. B. Histograms following staining of resident peritoneal macrophages or peritoneal macrophages 48, 96 and 120 hours after thioglycollate with anti-CD36 or isotype control (n=3-4 mice/time point). C. The mean fluorescent index (MFI) of CD36 is indicated for F4/80+ macrophages that are CD36+. D. The % of F4/80+ cells expressing CD36 is shown. Numbers within bars indicate the number of mice evaluated, and p values for significant differences are shown.

Figure 4: Adam17 deletion results in a 25% decrease in the ratio of soluble to cell- associated CD36. CD36 content and biochemical characteristics of microparticle-depleted conditioned medium and cell lysates from Adam17-null and WT peritoneal macrophages after the indicated incubation times were analyzed. A. CD36 levels in lysate and media were quantified by ELISA and expressed as the ratio of soluble to cellular CD36, and numbers within the bars indicate the number of mice of different genotypes whose macrophages were evaluated. These data are representative of 2 experiments. B. Soluble levels of CD36 and TNF receptor II were evaluated by ELISA following stimulation of WT peritoneal macrophages for 4 hours. Data is expressed relative to levels in PBS. Values are from two different experiments using macrophages from different mice determined in duplicate. C. and D. Western blot analysis of conditioned media from Adam17-null or WT peritoneal macrophages following deglycosylation with PNGase F. Each lane represents media collected from macrophages of different mice after the indicated time, and the collections for C are from a different experiment than shown in A.
Figure 5: Identification of novel proteolytic cleavage sites in soluble CD36. A. Topology and domains of CD36 and possible ADAM17 cleavage sites are indicated with arrows. Possible N-terminal ADAM17 cleavage sites are indicated with arrows. A hydrophobic region between amino acids 184-204 may interact with the plasma membrane, creating additional regions adjacent to the plasma membrane. All of the cysteine residues in CD36 are shown as a solid circle, and dotted lines indicate disulfide bonds determined from MS analysis. CD36 domain data particularly implicate the C-terminal cytoplasmic domain in assembly of signaling complexes that mediate its multiple functions. This diagram was adapted from Silverstein and Febbraio. B. Soluble CD36 immunoprecipitated from microparticle-depleted 24-hour-conditioned media was separated on SDS-PAGE following PNGase F treatment. Western showing three gel fractions (A, B, C) from the major regions of CD36 seen in Figure 4 and the area between were excised as indicated for mass spectrometric analysis. C. CD36 protein sequence is shown and peptides identified in the 3 gel slices are underlined, two putative transmembrane domains are in dark gray boxes, and a hydrophobic region that may interact with the plasma membrane is the gray box with dashed outline. The unique N-terminal peptides (N1, N2 and N3) and a C-terminal non-tryptic peptide (C1) are indicated by open black boxes. All of the indicated peptides were identified in at least 2 of 3 separate samples.

Figure 6: Enhanced efferocytosis by Adam17-null macrophages is abolished by CD36 blocking Fab and resolution of inflammation is accelerated in mice lacking leukocyte ADAM17. The in vivo apoptotic cell assay was performed as shown in Figure 1A. A. Fluorescently labeled apoptotic thymocytes, along with 80 µg of either isotype, or CD36-blocking Fab, were injected into the peritoneal cavity of Adam17-null and WT chimeric mice and TAMRA-positive macrophages assessed by flow cytometry. B. Total macrophage number in the peritoneal cavity was evaluated 30 min after injection of PBS, healthy thymocytes or apoptotic thymocytes to monitor the resolution of inflammation. The number of mice analyzed (within bars) and p values of significant differences are shown.
NOVELTY AND SIGNIFICANCE

What Is Known?

- Uptake of dying cells decreases inflammation and promotes its resolution.
- In chronic inflammation, uptake of dying cells is impaired and the levels of the soluble forms of their receptors are elevated.
- The proteolysis of cell surface receptors for dying cells can regulate the levels of these receptors on the surface of macrophages.

What New Information Does This Article Contribute?

- Deficiency of the transmembrane protease ADAM17 in macrophages increases in vivo uptake of dying cells.
- ADAM17 mediates the cleavage of the dual-pass apoptotic receptor CD36 and in Adam17-deficient mice enhanced uptake of dying cells is CD36-dependent.
- ADAM17 limits the uptake of dying cells, and thereby the resolution of inflammation.

Dysfunctional uptake of dying cells during chronic inflammation impairs resolution of inflammation, but the underlying mechanisms are poorly understood. Here we show that in vivo proteolysis by ADAM17 controls the levels of the scavenger receptor CD36 on macrophage surface and therefore limits the uptake of dying cells by this receptor. As a post-translational mechanism, ADAM17 proteolysis can rapidly regulate the inflammatory response, but our studies suggest that ADAM17-mediated effects are dependent upon both temporal and contextual modulation of CD36 expression. These findings suggest a potential mechanistic link between proteolysis, chronic inflammation and defective uptake of dying cells.
Figure 1: Increased \textit{in vivo} efferocytosis of apoptotic thymocytes by \textit{Adam17-null} macrophages is cell autonomous, and shifts them to a less inflammatory phenotype. 

\textbf{A} \textit{In vivo} analysis of apoptotic thymocyte uptake

The scheme for \textit{in vivo} peritoneal macrophage uptake of TAMRA-labeled apoptotic thymocytes is shown. Healthy thymocytes and opsonized thymocytes were evaluated as controls. 

\textbf{B} WT, \textit{Adam17-null}, or mixed hematopoietic chimera mice that have \textasciitilde{}50\% WT and \textasciitilde{}50\% \textit{Adam17-null} leukocytes were injected with the indicated thymocytes. The percent of TAMRA-positive macrophages was assessed by flow cytometry. 

\textbf{C} Following \textit{in vivo} exposure to PBS, healthy or apoptotic thymocytes, \textit{Adam17-null} or WT macrophages were analyzed immediately following harvest for intracellular levels of arginase I, or \textbf{D} cultured \textit{ex-vivo} for 20 hours with lipopolysaccharide and IFN\gamma and analyzed for intracellular iNOS by flow cytometry. Numbers in the bars indicate the number of mice evaluated, and \textit{p} values for significant differences are shown.
Figure 2: *Adam*17-null peritoneal and bone marrow-derived macrophages show increased phosphatidylserine liposome binding/uptake, and peritoneal macrophage uptake is CD36-dependent. **A.** Peritoneal macrophages from WT or *Adam*17-null hematopoietic chimera mice were harvested 96 hours after thioglycollate injection, and either plated and treated with or without acetylated-LDL at 4°C for 15 minutes followed by incubation with 40 μmol/L fluorescently labeled phosphatidylserine (PS) liposomes for 4 hours at 4°C. **B.** Bone-marrow-derived macrophages were isolated from whole bone marrow of WT or *Adam*17-null hematopoietic chimera mice and cultured for 7 days with M-CSF. Adherent cells were replated, and PS liposome binding was monitored as described in **A.** **C.** Peritoneal macrophages were plated and incubated with 160 μmol/L fluorescently labeled PS liposomes and 5 mg/L of either receptor-blocking or isotype control antibody for one hour at 37°C. Fluorescence was assessed by flow cytometry, numbers within the bars indicate the number of mice evaluated, and *p* values for significant differences are shown.
Figure 3: Cell surface levels of CD36 are elevated on peritoneal macrophages lacking ADAM17, and maximal expression of CD36 on WT macrophages is during the resolution phase of peritonitis. WT resident peritoneal macrophages (Res) or peritoneal macrophages from WT or Adam17-null hematopoietic chimera mice were harvested at different times after thioglycollate injection and immediately stained with antibodies to the indicated apoptotic cell receptors and evaluated by flow cytometry. A. Levels of different apoptotic cell receptors were evaluated 96 hours after thioglycollate. B. Histograms following staining of resident peritoneal macrophages or peritoneal macrophages 48, 96 and 120 hours after thioglycollate with anti-CD36 or isotype control (n=3-4 mice/time point). C. The mean fluorescent index (MFI) of CD36 is indicated for F4/80+ macrophages that are CD36+. D. The % of F4/80+ cells expressing CD36 is shown. Numbers within bars indicate the number of mice evaluated, and p values for significant differences are shown.
Figure 4: 

*Adam17* deletion results in a 25% decrease in the ratio of soluble to cell-associated CD36. CD36 content and biochemical characteristics of microparticle-depleted conditioned medium and cell lysates from *Adam17*-null and WT peritoneal macrophages after the indicated incubation times were analyzed. 

**A.** CD36 levels in lysate and media were quantified by ELISA and expressed as the ratio of soluble to cellular CD36, and numbers within the bars indicate the number of mice of different genotypes whose macrophages were evaluated. These data are representative of 2 experiments. 

**B.** Soluble levels of CD36 and TNF receptor II were evaluated by ELISA following stimulation of WT peritoneal macrophages for 4 hours. Data is expressed relative to levels in PBS. Values are from two different experiments using macrophages from different mice determined in duplicate. 

**C. and D.** Western blot analysis of conditioned media from *Adam17*-null or WT peritoneal macrophages following deglycosylation with PNGase F. Each lane represents media collected from macrophages of different mice after the indicated time, and the collections for C are from a different experiment than shown in A.
Figure 5: Identification of novel proteolytic cleavage sites in soluble CD36. A. Topology and domains of CD36 and possible ADAM17 cleavage sites are indicated with arrows. Possible N-terminal ADAM17 cleavage sites are indicated with arrows. A hydrophobic region between amino acids 184-204 may interact with the plasma membrane, creating additional regions adjacent to the plasma membrane. All of the cysteine residues in CD36 are shown as a solid circle, and dotted lines indicate disulfide bonds determined from MS analysis. CD36 domain data particularly implicate the C-terminal cytoplasmic domain in assembly of signaling complexes that mediate its multiple functions.

B. Soluble CD36 immunoprecipitated from microparticle-depleted 24-hour-conditioned media was separated on SDS-PAGE following PNGase F treatment. Western showing three gel fractions (A, B, C) from the major regions of CD36 seen in Figure 4 and the area between were excised as indicated for mass spectrometric analysis. C. CD36 protein sequence is shown and peptides identified in the 3 gel slices are underlined, two putative transmembrane domains are in dark gray boxes, and a hydrophobic region that may interact with the plasma membrane is the gray box with dashed outline. The unique N-terminal peptides (N1, N2 and N3) and a C-terminal non-tryptic peptide (C1) are indicated by open black boxes. All of the indicated peptides were identified in at least 2 of 3 separate samples.
Figure 6: Enhanced efferocytosis by Adam17-null macrophages is abolished by CD36 blocking Fab and resolution of inflammation is accelerated in mice lacking leukocyte ADAM17. The in vivo apoptotic cell assay was performed as shown in Figure 1A. A. Fluorescently labeled apoptotic thymocytes, along with 80 µg of either isotype, or CD36-blocking Fab, were injected into the peritoneal cavity of Adam17-null and WT chimeric mice and TAMRA-positive macrophages assessed by flow cytometry. B. Total macrophage number in the peritoneal cavity was evaluated 30 min after injection of PBS, healthy thymocytes or apoptotic thymocytes to monitor the resolution of inflammation. The number of mice analyzed (within bars) and p values of significant differences are shown.
Macrophage ADAM17 Deficiency Augments CD36-Dependent Apoptotic Cell Uptake and the Linked Anti-Inflammatory Phenotype
Will S. Driscoll, Tomas Vaisar, Jingjing Tang, Carole L. Wilson and Elaine W. Raines

Circ Res. published online April 12, 2013;
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/early/2013/04/12/CIRCRESAHA.112.300683

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2013/04/12/CIRCRESAHA.112.300683.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
Online material

**Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype**

Will S. Driscoll¹, Tomas Vaisar², Jingjing Tang¹, Carole L. Wilson¹, and Elaine W. Raines'

Departments of ¹Pathology and ²Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington School of Medicine, Seattle, WA

*Running title: ADAM17 limits CD36-mediated apoptotic cell uptake*

*Address correspondence to:*
Elaine W. Raines
University of Washington School of Medicine
Department of Pathology
Harborview Medical Center, Box 359675
325 - 9th Avenue
Seattle, WA 98104
Office phone: (206) 897-5410
Lab phone: (206) 897-5411
Fax: (206) 897-5416
e-mail: ewraines@u.washington.edu
DETAILED METHODS

Hematopoietic chimeric mice

Adam17\(^{\Delta \text{Ex5/\Delta \text{Ex6}}}\) (Adam17 \(-/-\)) or wildtype hematopoietic chimeras were generated as previously described using C57BL/6 ES cells.\(^1, 2\) All animals used for studies were second generation hematopoietic chimeras (C57BL/6, Jackson Laboratory stock #000664) repopulated with bone marrow from first generation fetal liver chimeras. To prepare mixed hematopoietic chimeras, bone marrow cells for transplantation were a 50:50 mixture of Ly5.1-expressing C57BL/6J bone marrow (B6.SJL-Ptrc\(^a\) Ppec\(^b\)/BoyJ, Jackson Laboratory stock #002014) and Adam17\(-/-\) cells (Ly5.2) to repopulate C57BL/6J recipients (C57BL/6, Jackson Laboratory stock #000664). All mouse experiments were approved by the University of Washington Institutional Animal Care and Use Committee.

Preparation of bone-marrow-derived macrophages

Bone marrow was harvested from wildtype and Adam17\(-/-\) hematopoietic chimeras, plated and incubated with 1,000,000 U/L human macrophage colony-stimulating factor (gift from Chiron) for 7 days. Bone-marrow-derived macrophages were incubated under different conditions for evaluation CD36 levels in conditioned media and cell lysates or used for liposome binding studies, following replating to establish comparable cell densities.

Flow cytometry

Staining of freshly isolated cells for flow cytometric analyses used the following antibodies: anti-CD36 (clone CRF D-2712, gift from Roy Silverstein),\(^3\) guinea pig polyclonal anti-SR-A (gift from Debra Rateri),\(^4\) anti-SR-BI (Novus, NB400-113), anti-Mer tyrosine kinase (R&D Systems, AF591), PE-anti-LOX-1 (R&D Systems, FAB1564P), and PerCP-Cy5.5-anti-CD45.2 (BD Pharmingen, 552950). For analysis of intracellular staining, cells were fixed on ice with 2% paraformaldehyde for 45 minutes, permeabilized with ice-cold methanol for 8 hours or more at \(-80^\circ\text{C}\) and stained with antibodies for arginase I (BD Transduction Laboratories, 610708) and inducible nitric oxide synthetase (iNOS; Abcam, ab15323).\(^5\) Nonspecific binding was blocked with anti-CD16/32 (BD Pharmingen, 553142). Unconjugated antibodies were fluorescently labeled using Zenon Antibody Labeling Kits (Invitrogen), or detected with FITC-anti-IgY (AnaSpec, 29709-FITC), FITC-anti-IgG (Molecular Probes, A21441), or FITC-anti-IgA (eBioscience, 11-4204-81). Stained cells were analyzed on a FACScan (BD Pharmingen), and 10,000-50,000 events were collected for each analysis. Flow data were analyzed using FlowJo 7.5 software (TreeStar).

Fab preparation

Protein-L affinity purified IgA from hybridoma culture media (anti-CD36, Clone CRF-D 2717, gift from Dr. Roy Silverstein), or non-immune IgA (Sigma Aldrich, M-1421), was partially reduced to facilitate papain cleavage.\(^6\) Immobilized papain (Pierce, 20341) was used to generate Fab fragments. The amount of Fab (80 \(\mu\)g per cavity) used for \textit{in vitro} blocking studies was based on \textit{in vitro} titrations of Fab sufficient to block phosphatidylserine liposome binding to thioglycollate-elicited macrophages. Endotoxin
levels in Fab preparations were determined by bioassay using THP1-XBlue reporter cells (Invivogen). Levels were below 10 pg endotoxin/80 µg Fab; a dose known not to affect the cellular influx into the peritoneal cavity.

**In vivo efferocytosis**

Thymuses harvested from 4-6 week old C57BL/6 mice were dissociated by mechanical disruption and filtered using a 70 µm cell strainer (BD Falcon, 352350) to yield a single-cell suspension. Thymocytes were labeled using the red fluorescent TAMRA-SE dye (Molecular Probes, C-1171). Briefly, 100 µg of TAMRA-SE was used to label 60 x 10^6 thymocytes suspended in DMEM at 37°C for 15 minutes. Excess label was quenched with fetal bovine serum, and the cells were washed. Apoptosis was then induced by treatment with 1 µmol/L dexamethasone in RPMI 1640 medium with 10% fetal bovine serum and 3.4 µl/L β-mercaptoethanol for 5 hrs at 37°C, yielding a population of thymocytes that were 60-80% Annexin V positive. Opsonized control cells did not receive dexamethasone treatment, and were generated by incubation with 5 µg anti-CD45 antibody (Pharmingen, 01111D) per 10x10^7 cells for 15 minutes at 4°C. To evaluate apoptotic cell uptake, 1x10^7 fluorescently labeled apoptotic thymocytes were injected into the peritoneum of ADAM17 null or wildtype chimeric mice 4 days after peritoneal injection of thioglycollate, in some experiments with 80 µg receptor-blocking Fab or isotype control Fab. Peritoneal cells were harvested 30 minutes after thymocyte injection with 5 ml PBS containing 5 mmol/L EDTA, and the percent of F4/80- stained macrophages positive for TAMRA-labeled thymocytes was assessed by flow cytometry. In trial experiments, we quantified uptake by both flow cytometry and by fluorescent microscopy (Online Figure I; only yellow apoptotic cells were counted, both TAMRA+ and F4/80+), and the data showed good agreement between the two methods (data not shown).

**Liposome binding and uptake**

Phospholipids were purchased from Avanti Polar Lipids. Phosphatidylserine (PS) rich liposomes, composed of equal parts PS to phosphatidylcholine, were prepared with a 1% mole fraction of the fluorescent dye, 1-dioctadecyl-3,3-tetramethylindocarbocyanin perchlorate (Dil, Sigma, 42364) by extrusion through a 0.1 µm polycarbonate membrane. Thioglycollate-elicited cells from wildtype or ADAM17 null hematopoietic chimeras, or 5-7 day bone-marrow-derived macrophages were plated on tissue culture dishes and macrophages (> 95%) adherent after 2 hours were used for binding and uptake studies. Macrophages were incubated with 160 µmol/L fluorescently-labeled PS liposomes and 5 mg/L of either receptor blocking (anti-CD36, CRF D-2712; anti-SR-A, R&D Systems AF1797) or isotype control antibodies. The cells were incubated for one hour at 37°C, and fluorescent liposome binding/uptake was assessed by flow cytometry. Acetylated-low-density lipoprotein (acLDL) was prepared by treatment of 10 mg of LDL (1.063 > d > 1.019 g/ml) in 50% saturated ice-cold sodium acetate with 15 mg acetic anhydride. For some *in vitro* binding analyses, adherent macrophages were treated with or without acLDL for 15 minutes prior to the addition of 40 µmol/L fluorescently-labeled PS liposomes and a 4-hour incubation at 4°C. Fluorescent liposome binding was evaluated by flow-cytometry.
Soluble CD36 characterization

Thioglycollate-elicited macrophages were plated 2 hours in tissue culture dishes and adherent cells were treated with 1,000,000 U/L human macrophage colony-stimulating factor (gift from Chiron) in Opti-MEM (Invitrogen) for 24 hours at 37° C. Conditioned media was removed and centrifuged at 300 x g for 10 minutes to remove cell debris. The media was then centrifuged at 28,300 x g for 140 minutes at 4°C to deplete microparticle content. The resulting media was concentrated 20-fold by ultrafiltration (Orbital Biosciences AP2000910), and immuno-precipitated with anti-CD36 antibody (CRF D-2712) covalently coupled to agarose (Pierce 26198). Immunoprecipitated protein was eluted by boiling in non-reducing SDS-sample buffer, and precipitated overnight at 4° C in 15% TCA (Sigma T0699). The precipitate was washed with acetone, dried, re-suspended, and digested with PNGase F (New England Biolabs, P0704S). SDS-PAGE was carried out using 10% acrylamide gels, and Western blotting was performed following semi-dry transfer onto PVDF membranes using biotinylated anti-CD36 (R&D BAF2519), streptavidin conjugated horseradish peroxidase (Jackson ImmunoResearch 016-030-084), and SuperSignal West Femto developing reagent (Thermo).

Identification of the putative CD36 cleavage site

Gel bands corresponding to CD36 were detected by Coomassie staining, and were verified by CD36 immunoblot analysis of adjacent lanes in the same gel. Bands corresponding to CD36 were excised and subjected to standard in-gel digestion with trypsin. Digested peptides extracted from the gel pieces were dried down and reconstituted for liquid chromatography-mass spectrometry (LCMS) analysis in 5% acetonitrile/0.1% trifluoroacetic acid. The peptides were then injected onto a C18 trap column (XBridge C18 100A, 5 µm, 0.1 x 30 mm, Waters), desalted for 15 minutes with water/0.1% formic acid (4 µL/minute), eluted onto an analytical column (XBridge C18 100A, 3.5 µm, 0.1 x 100 mm, Michrom Bioresources, Inc.) heated to 45° C and separated at a flow rate of 0.5 µL/minute over 90 minutes, using a linear gradient of 5% to 35% acetonitrile/0.1% formic acid in 0.1% formic acid on a NanoAquity HPLC (Waters, Milford, MA). Positive ion mass spectra were acquired with electrospray ionization in a hybrid linear ion trap-Orbitrap mass spectrometer (LTQ Orbitrap XL, Thermo Fisher, San Jose, CA) or Q Exactive mass spectrometry (Thermo Fisher, Dan Jose, CA) with data-dependent acquisition of MS/MS scans (linear ion trap) on the 8 most abundant ions (20 for Q Exactive) in the survey scan (orbitrap, resolution 30,000). An exclusion window of 45 seconds was used after 2 repeated acquisitions of the same precursor ion.

For protein identification, MS/MS spectra were matched against the mouse Uniprot/SwissProt database using the SEQUEST (v 2.7) search engine with fixed Cys carbamidomethylation and variable Met oxidation modifications and no enzyme specificity (semi-specific restriction was applied on the results of the database search). The mass tolerance for precursor ions was 50 ppm (MS1 data); SEQUEST default tolerance was accepted for product ions. SEQUEST results were further validated with PeptideProphet and ProteinProphet, using an adjusted probability of ≥ 0.90 for peptides and ≥ 0.95 for proteins. Each charge state of a peptide was considered a unique identification. Identity of the semi-specific trypsin proteolytic fragment was further
confirmed by Mascot database search (v 2.1, mouse SwissProt database, Matrix Science, UK) on the MS/MS spectrum of the m/z 1045.5 (semi-tryptic specificity, mass tolerance 50 ppm precursor, 0.4 Da fragments, modifications - fixed Cys+57.021, variable Met+15.99).

CD36 ELISA
Both antibodies used for the ELISA recognize the extracellular domain of CD36. 96-well plates (Nunc-Immuno 62409-003) were coated overnight at room temperature with 50 µl/well of 0.5 µg/L anti-CD36 capture antibody (CRF D-2712) in PBS. Wells were blocked with 100ul of 1% BSA in 0.05% Tween-20 PBS for 2 hrs at room temperature. Samples were diluted in 20 mmol/L Tris pH 7.4, 150 mmol/L NaCl, 0.1% BSA, 0.05% Tween-20, and added to the plate in a volume of 50 µl and incubated for 2 hours. A reference standard was prepared by dilution of pooled 96-hour thioglycollate-elicited peritoneal macrophage lysate. CD36 was detected using 400 µg/L biotinylated anti-CD36 (R&D BAF2519) for 2 hours, followed by 1.5 mg/L streptavidin-HRP (Jackson ImmunoResearch, 016-030-084) for 30 minutes. Plates were developed by the addition of 50 µl tetramethylbenzidine substrate reagent (R&D, DY999). After 15 minutes, the reaction was stopped by the addition of 2N sulfuric acid, and absorbance at 450 nm was measured using a SpectraMax 2Me spectrophotometer.

Primer pairs
All primer pairs to detect different ADAM proteases were designed to generate ~ 400bp fragments:

- **ADAM2**: forward 5’-ACC GAT TAT GTT GGC GCT AC-3’, reverse 5’-TTT CTG CAC AGC CCT TCT TT-3’;
- **ADAM8**: forward 5’-TGT CCT GGA GGG AAC AGA AC-3’, reverse 5’-AAC CGG TTG ACA TCT GGA AC-3’;
- **ADAM9**: forward 5’-CAT GAA TTG GGG CAT AAC CT-3’, reverse 5’-CTC ACT GGT CCT CCC TCT GC-3’;
- **ADAM10**: forward 5’-AGC AAC ATC TGG GGA CAA AC-3’, reverse 5’-TAA AGT TGG GCT TGG GAT CA-3’;
- **ADAM12**: forward 5’-AGA GAA AGG AGG CTG CAT CA-3’, reverse 5’-ACA CAT TGG CTG GAC AGT GA-3’;
- **ADAM15**: forward 5’-ACA AGC ATC TTA GGC GTT GC-3’, reverse 5’-TTT GAC AAC AGG GTC CAT CA-3’;
- **ADAM17**: forward 5’-TTG AGC GAT TTT GGG ATT TC-3’, reverse 5’-GTT CCT TCT CAA ATC CGT CA-3’;
- **ADAM19**: forward 5’-ATT GCC TCC AAC TGC ACT CT-3’, reverse 5’-ATC TTC CCA CAC TTG GCA TC-3’;
- **ADAM33**: forward 5’-CCA CAC GAC TCC ACA CAA CT-3’, reverse 5’-CTT CCA AGA AGC CGT TTC C-3’.
Online Figure I: Immunofluorescent microscopy is consistent with uptake of apoptotic cells. Representative microphage of F4/80-stained macrophages (green) obtained from a wildtype ADAM17 hematopoietic chimera injected intraperitoneally with TAMRA-labeled (red) apoptotic thymocytes as described in Figure 1A. Quantification of thymocyte uptake by fluorescence microscopy was in agreement with flow cytometry data (data not shown).
Online Figure II: Representative histograms of intracellular Arginase I and iNOS show the shift to a less inflammatory phenotype in macrophages lacking ADAM17. Histograms of intracellular levels of A. Arginase I and B. iNOS for wildtype macrophages (blue) and Adam17-null macrophages (red).
Online Figure III: Spectra from three unique N-terminal peptides with non-tryptic N-terminal sequences and one C-terminal peptide, which were identified with high confidence in soluble CD36. The spectra shown were identified with high confidence in at least 2 of 3 separate samples: A. N1, PeptideProphet probability 0.98, delta mass 3.59 ppm; B. N2, PeptideProphet probability 0.975, delta mass 2.7 ppm; C. N3, PeptideProphet probability 0.95, delta mass 6.96 ppm; and D. C1, PeptideProphet probability 1.0, delta mass 3.0 ppm.
Online Figure IV: Multiple ADAMs containing protease domains are expressed by mouse peritoneal and bone marrow-derived macrophages. Total RNA was isolated from peritoneal (pMAC) and bone marrow-derived (BMDM) macrophages, reverse transcribed and the resulting cDNA was amplified with primer pairs specific to the indicated ADAMs. Products were separated on a 1.2% agarose gel and stained with ethidium bromide.
ONLINE REFERENCES